NVB treatment of immunocompetent mice bearing Brca-deficient tumors also resulted in an increased proportion of CD11c+CD11b− DCs in the tumor microenvironment (Supplementary Fig. 2a). The gene discussed is ITGAX; the disease is neoplasm.